Screener
Adaptive Biotechnologies ADPT Total Cost of Revenue
Total Cost of Revenue at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206546
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Revenue | $70,874 | $52,443 |
| Operating expenses | ||
| Cost of revenue | 18,708 | 16,979 |
| Research and development | 23,623 | 24,203 |
| Sales and marketing | 26,346 | 23,047 |
| General and administrative | 20,984 | 17,399 |
| Amortization of intangible assets | 419 | 419 |
| Total operating expenses | 90,080 | 82,047 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Adaptive Biotechnologies's total cost of revenue?
- Adaptive Biotechnologies (ADPT) reported total cost of revenue of $18.71M in Q1 2026.
- How has Adaptive Biotechnologies's total cost of revenue changed year-over-year?
- Adaptive Biotechnologies's total cost of revenue increased by 10.2% year-over-year, from $16.98M to $18.71M.
- What is the long-term trend for Adaptive Biotechnologies's total cost of revenue?
- Over 4 years (2021 to 2025), Adaptive Biotechnologies's total cost of revenue has grown at a 9.7% compound annual growth rate (CAGR), from $49.3M to $71.36M.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.
Ask your AI about Adaptive Biotechnologies's total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude